Form 4: Sutro Biopharma Executive Barbara Leyman Reports Stock Option and RSU Grants

Barbara Leyman, Chief Business Development Officer of Sutro Biopharma, reports the acquisition of stock options and restricted stock units (RSUs) on April 4, 2025.

Summary

• Barbara Leyman, Chief Business Development Officer at Sutro Biopharma, filed a Form 4 on April 8, 2025, reporting changes in beneficial ownership.
• On April 4, 2025, Leyman acquired stock options for 91,000 shares of common stock at an exercise price of $0.55 per share.
• These options vest monthly starting May 4, 2025, and will be fully vested by April 4, 2029, contingent upon continued service to the issuer.
• Leyman also acquired 84,500 Restricted Stock Units (RSUs) on April 4, 2025.
• These RSUs vest annually, starting March 2, 2026, with full vesting by March 2, 2029, also contingent upon continued service.
• Each RSU represents the right to receive one share of Sutro Biopharma's common stock upon settlement.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grants are standard practice and incentivize the executive, which is generally viewed favorably. There are no immediate negative implications.

Positives

• The grant of stock options and RSUs to the Chief Business Development Officer aligns her interests with those of the shareholders.
• The vesting schedules for both the options and RSUs incentivize continued service and commitment to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the options and RSUs.

Industry Context

Granting stock options and RSUs is a common practice in the biopharmaceutical industry to attract, retain, and incentivize key executives. These grants align executive compensation with company performance and shareholder value.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for executives in biotech companies like Sutro Biopharma.
• Companies such as Amgen, Gilead, and Biogen also utilize similar equity-based compensation plans to incentivize their leadership teams.
• The vesting schedules (monthly for options, annually for RSUs) are typical within the industry, promoting long-term commitment.
• The specific number of options and RSUs granted would be benchmarked against peer companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view the grants positively as they align executive interests with company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Form 4, Sutro Biopharma, Stock Options, RSUs, Beneficial Ownership, Barbara Leyman, STRO